<DOC>
	<DOCNO>NCT02999841</DOCNO>
	<brief_summary>Focusing newly diagnose type 2 diabetes participant overweight obesity ( 24kg/m2 ≤ body mass index ≤ 30kg/m2 ) . 50 participant per arm ( acarbose &amp; lifestyle combination / vildagliptin &amp; lifestyle combination ) , use abdominal compute tomography scan method evaluate effect acarbose vildagliptin visceral fat distribution overweight obesity patient newly diagnose type 2 diabetes .</brief_summary>
	<brief_title>Effect Acarbose Vildagliptin Visceral Fat Distribution Newly Diagnosed Type 2 Diabetes Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Acarbose</mesh_term>
	<criteria>All patient diagnose within past 12 month type 2 diabetes patient ( WHO , 1999 criterion ) . Not received oral antidiabetic drug shortterm ( 1month ) treatment discontinue 3 month enrollment . 30 ≤ Age ≤ 70 year old , male female . HbA1c 7 % 9 % ( 7.0 % ≤ HbA1c ≤9.0 % ) . 24 ≤ BMI ≤ 30 kg/m2 . Written Informed consent . Subject type 1 diabetes gestational diabetes mellitus specific type DM . Those tolerate AGI suffer GI disease . Subject repeat severe hypoglycemia and/or unawareness hypoglycemia . Known suspect allergy trial product ( ) relate product . Females child bear potential pregnant , breastfeed intention become pregnant use adequate contraceptive method throughout trial Impaired liver function , define ALT≥2 AST≥ 2 time upper reference limit time upper normal limit . Any clinically significant condition major systemic disease , include serious coronary heart disease , cardiovascular disease , cancer , TB , acute infection . Endocrine disease ( hypo thyroidism , hyperthyroidism , Cushing 's syndrome ) . Uncontrolled hypertension ( SBP≥180mmHg and/or DBP≥100mmHg ) . Diabetic ketoacidosis ; hyperosmolar nonketotic coma . Concomitant treatment influence blood glucose bodyweight . Impaired renal function ( Cr≥ 1.5 mg/dl male Cr≥1.4 mg/dl female ) . Mental disorder ; drug substance misuse . Participation drug clinical trial past 3 month enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Visceral fat</keyword>
</DOC>